Abstract
This open prospective study assessed the use of gabapentin in migraine and epilepsy comorbid with mood and anxiety disorders. After a 4-week baseline period, gabapentin was used as adjunctive treatment in 14 adult patients with both epilepsy and migraine disorders for 3 months. The outcomes were compared with a control group of 14 sex-matched patients with the same disorders, not treated with gabapentin. Both groups were assessed on the Cornell dysthymia rating scale (CDRS), Beck depression inventory (BDI), and Hamilton anxiety scale. A total of 8 (57%) gabapentin-treated patients showed a significant improvement in migraine vs. 3 (21.4%) of the controls. In comparison with controls, the gabapentin-treated group had a significant decrease in CDRS and BDI scores (p<0.05). The results suggest a particular role for gabapentin in the treatment of patients with both epilepsy and migraine comorbid with mood and anxiety disorders.